Catalyst Wire Dossier Catalyst Wire Dossier
CLINICAL_TRIALS trial_result · 2015-01-07

Clinical Trial Update: IMAAGEN: Impact of Abiraterone Acetate in Prostate-Specific Antigen [Phase 2]

View source ↗

Summary

A Phase 2 trial evaluating abiraterone acetate's effect on PSA in men with prostate cancer completed and results were posted in 2015.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

Drugs mentioned

  • Abiraterone acetate (Abiraterone acetate)

Snippet

Sponsor: Janssen Biotech, Inc. | Conditions: Prostate Cancer, Prostatic Neoplasm | Phase 2 | Status: COMPLETED | Results posted: 2015-01-07